Clinical Trial

A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD

Name: A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD — clinical trial record (NCT07086313)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-07-17.

Trial Details

NCT Number	NCT07086313
Lead Sponsor	Otsuka Pharmaceutical Co., Ltd.
Conditions	Attention-Deficit Hyperactivity Disorder(ADHD)
Enrollment	315 participants
Start Date	2025-09-03
Primary Completion	2027-08 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2025-12-23